Clinical trials: Schizoaffective
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients in Integrated Care
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- CARE II (NCT00681629)
- Testing
- Quetiapine XR, Integrated Care Program (ICP)
- Where
- 8 sites in Germany
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse
- Trial name
- NCT00156715
- Testing
- Quetiapine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
The purpose of this study is to evaluate the long-term efficacy and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) and its influence on quality of life, in participants with…
- Trial name
- NCT00269919
- Testing
- Risperidone Long-Acting Injectable (RLAI)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Schizoaffective Disorder
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
Purpose: The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments have gained widespread use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Overweight
- Trial name
- MELT (NCT02796144)
- Testing
- Lorcaserin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Systematic Evaluation of Antiviral Medication in Schizophrenia
The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes…
- Trial name
- SEAMS (NCT00514449)
- Testing
- Valacyclovir
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Konasale Prasad
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00337662
- Testing
- olanzapine, risperidone
- Where
- 34 sites in United States, Argentina and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00330551
- Testing
- Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Kynurenic acid (KYNA) is a naturally occurring chemical in the brain. Studies with rodents indicate that levels of KYNA can impact levels of the neurotransmitters glutamate and dopamine.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- TrypNAC-II (NCT04013555)
- Testing
- N-acetylcysteine (NAC), Tryptophan
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation to Clozapine
The proposed pilot study will compare minocycline augmentation with clozapine in individuals with high vs low inflammation as measured by CRP.
- Trial name
- NCT02124811
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
This program aims to help Veterans who take antipsychotic medications lose weight. We use a program based on the American Diabetes Association's "Diabetes Prevention Program," and we have modified it to fit the lifestyles of…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO2 (NCT01052714)
- Testing
- Lifestyle Balance
- Where
- 3 sites in United States
- Volunteers
- 121 people
- Sponsor
- VA Office of Research and Development
Schizoaffective Disorder, Schizophrenia
Motivational Interviewing to Improve Work Outcomes in Schizophrenia
Many persons with schizophrenia have difficulty getting and keeping a job. This study is designed to compare the benefits of four sessions of motivational interviewing or illness education in increasing employment rates accruing…
- Trial name
- NCT00261716
- Testing
- IPS, IE, VOMI
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- VA Office of Research and Development
Psychotic Disorders, Schizoaffective Disorder
Functional Rehabilitation of Older Patients With Schizophrenia
The primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (CBSST), that teaches social functioning skills and cognitive-behavioral compensatory…
- Conditions
- Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT00237796
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- US Department of Veterans Affairs
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01929889
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Virtual Reality Job Interview Training in Severe Mental Illness
This is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (VR-JIT). Northwestern University is partnering with Thresholds Inc.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT03049813
- Testing
- Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Michigan